drugset / Trial / NCT00191035

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

NCT00191035

Phase 4 Completed 520 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks

Timeline

Start
2004-03
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 0.8 mg/kg
Subject Atomoxetine Other / unclassified 1.4 mg/kg